Azvudine

Azvudine is an antiviral medication developed by Genuine Biotech in China. It is a nucleoside reverse transcriptase inhibitor (NRTI) initially approved for the treatment of HIV-1 infection.

Mechanism of Action: Azvudine works by inhibiting the reverse transcriptase enzyme of retroviruses, including HIV-1. This enzyme is crucial for the replication of the virus, as it converts viral RNA into DNA, which is then integrated into the host cell's genome. By inhibiting reverse transcriptase, azvudine prevents the virus from replicating and spreading within the body.

Clinical Use:

• HIV-1 Infection: Azvudine is approved in China for the treatment of HIV-1 infection in combination with other antiretroviral drugs.
• COVID-19: Azvudine has also been studied for its potential efficacy in treating COVID-19. In July 2022, it received conditional approval in China for the treatment of adult patients with moderate COVID-19.

Administration: Azvudine is typically administered orally. Dosage regimens vary depending on the specific indication and patient population.

Side Effects: Common side effects associated with azvudine use can include, but are not limited to, nausea, vomiting, diarrhea, and dizziness. More serious side effects are possible but less frequent.

Contraindications: Azvudine may be contraindicated in certain individuals, such as those with known hypersensitivity to the drug or certain pre-existing medical conditions.

Drug Interactions: Azvudine may interact with other medications, so it is important for patients to inform their healthcare providers of all drugs they are taking.

Regulatory Status: Azvudine is currently approved for use in China. Its regulatory status in other countries may vary.